BioNTech SE

BioNTech's oncology pipeline, including bispecific antibody pumitamig developed with Bristol Myers Squibb, shows encouraging anti-tumor activity and high response rates across NSCLC subtypes. UBS upgraded the stock to Buy with a $135 price target, validating the company's strategic pivot toward cancer therapeutics as a credible long-term growth engine.

Analysts have flagged pipeline uncertainties and regulatory headwinds around mRNA technology, raising concerns that the oncology transition may not adequately offset the steep decline in COVID-19 vaccine revenues, which contributed to a 2024 net loss of €665M and a $1.14B net loss in 2025 with persistently negative margins.

Despite near-term headwinds, 15 out of 20 analysts maintain a Buy rating on BNTX with an average 12-month price target of $122.16, representing over 33% upside from current levels. The consensus reflects confidence in BioNTech's financial health and long-term revenue recovery potential from its diversified pipeline.

Analysts anticipate a sales decline in the current year, and BioNTech's 5-year EPS growth forecast stands at a deeply negative -42.96%. Firms like Bernstein SocGen Group and JPMorgan have initiated coverage with Hold ratings and conservative price targets of $96 and $100 respectively, signaling skepticism about near-term financial recovery.

Fundamental analysts maintain a strong Buy consensus across major platforms, with an average price target of $122–$139 and up to 14–20 analysts recommending the stock. The Trend Seeker® indicator on Barchart also registers a Buy signal with a strengthening direction, suggesting potential upside momentum building.

Technical indicators paint a starkly different picture: Barchart's overall average signal reads 56% Sell, with long-term moving averages (100-day, 150-day, 200-day) all flashing Sell. The stock trades near the lower end of its 52-week range of $79.52–$124.00, reflecting persistent price weakness and negative market momentum.